Literature DB >> 33537306

OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1.

Yihao Liao1, Ning Wu2,3, Keke Wang1, Miaomiao Wang1, Youzhi Wang1, Jie Gao1, Boqiang Zhong1, Fuling Ma1, Yudong Wu4, Ning Jiang1.   

Abstract

Background: Prostate cancer (PCa) is currently the most common cancer among males worldwide. It has been reported that OTUB1 plays a critical role in a variety of tumors and is strongly related to tumor proliferation, migration, and clinical prognosis. The aim of this research is to investigate the regulatory effect of OTUB1 on PCa proliferation and the underlying mechanism.
Methods: Using the TCGA database, we identified that OTUB1 was up-regulated in PCa, and observed severe functional changes in PC3 and C4-2 cells through overexpression or knock down OTUB1. Heterotopic tumors were implanted subcutaneously in nude mice and IHC staining was performed on tumor tissues. The relationship between OTUB1 and cyclin E1 was identified via Western blotting and immunoprecipitations assays.
Results: We found that the expression of OTUB1 in PCa was significantly higher than that in Benign Prostatic Hyperplasia (BPH). Overexpression OTUB1 obviously promoted the proliferation and migration of PC3 and C4-2 cells via mediating the deubiquitinated Cyclin E1, while OTUB1 knockout has the opposite effect. The nude mice experiment further explained the above conclusions. We finally determined that OTUB1 promotes the proliferation and progression of PCa via deubiquitinating and stabling Cyclin E1. Conclusions: Our findings reveal the critical role of OTUB1 in PCa, and OTUB1 promotes the proliferation and progression of PCa via deubiquitinating and stabilizing Cyclin E1. Blocking OTUB1/Cyclin E1 axis or applying RO-3306 could significantly repress the occurrence and development of PCa. OTUB1/Cyclin E1 axis might provide a new and potential therapeutic target for PCa.
Copyright © 2021 Liao, Wu, Wang, Wang, Wang, Gao, Zhong, Ma, Wu and Jiang.

Entities:  

Keywords:  OTUB1; cyclin E1; progression; proliferation; prostate cance

Year:  2021        PMID: 33537306      PMCID: PMC7848094          DOI: 10.3389/fcell.2020.617758

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  6 in total

1.  Phosphorylation of OTUB1 at Tyr 26 stabilizes the mTORC1 component, Raptor.

Authors:  Seung Un Seo; Seon Min Woo; Min Wook Kim; Eun-Woo Lee; Kyoung-Jin Min; Taeg Kyu Kwon
Journal:  Cell Death Differ       Date:  2022-08-04       Impact factor: 12.067

2.  OTUB1 augments hypoxia signaling via its non-canonical ubiquitination inhibition of HIF-1α during hypoxia adaptation.

Authors:  Xing Liu; Hongyan Deng; Jinhua Tang; Zixuan Wang; Chunchun Zhu; Xiaolian Cai; Fangjing Rong; Xiaoyun Chen; Xueyi Sun; Shuke Jia; Gang Ouyang; Wenhua Li; Wuhan Xiao
Journal:  Cell Death Dis       Date:  2022-06-22       Impact factor: 9.685

3.  Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis.

Authors:  Xue Han; Chune Ren; Chao Lu; Pengyun Qiao; Tingting Yang; Zhenhai Yu
Journal:  Cell Death Differ       Date:  2022-03-16       Impact factor: 12.067

4.  The deubiquitinase OTUB1 fosters papillary thyroid carcinoma growth through EYA1 stabilization.

Authors:  Peiyi Xie; Qing Chao; Jiuang Mao; Yue Liu; Jiayu Fang; Jing Xie; Jing Zhen; Yongqi Ding; Bidong Fu; Yun Ke; Da Huang
Journal:  J Cell Mol Med       Date:  2021-11-12       Impact factor: 5.310

5.  Overexpression of OTU domain-containing ubiquitin aldehyde-binding protein 1 exacerbates colorectal cancer malignancy by inhibiting protein degradation of β-Catenin via Ubiquitin-proteasome pathway.

Authors:  Daoxiong Ye; Sisi Wang; Xiaojie Wang; Yu Lin; Ying Huang; Pan Chi
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 6.  Ubiquitin specific peptidase 11 as a novel therapeutic target for cancer management.

Authors:  Yihao Liao; Diansheng Zhou; Pu Wang; Mengyue Yang; Ning Jiang
Journal:  Cell Death Discov       Date:  2022-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.